Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating rituximab plus dexamethasone in patients with low-grade non-Hodgkin lymphoma, including follicular and marginal zone lymphomas; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous B-cell Non-hodgkin Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Malt
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Nodal Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Splenic Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-22